<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66721</article-id><article-id pub-id-type="doi">10.7554/eLife.66721</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-225994"><name><surname>Harada</surname><given-names>Akikazu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225995"><name><surname>Matsumoto</surname><given-names>Shinji</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225996"><name><surname>Yasumizu</surname><given-names>Yoshiaki</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9872-4909</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225997"><name><surname>Akama</surname><given-names>Toshiyuki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-225998"><name><surname>Eguchi</surname><given-names>Hidetoshi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-43161"><name><surname>Kikuchi</surname><given-names>Akira</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3378-9522</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Molecular Biology and Biochemistry, Graduate School of Medicine</institution>, <institution>Osaka University</institution>, <addr-line><named-content content-type="city">Suita</named-content></addr-line>, <country>Japan</country></aff><aff id="aff2"><institution content-type="dept">Laboratory of Experimental Immunology, WPI Frontier Immunology Research Center</institution>, <institution>Osaka University</institution>, <addr-line><named-content content-type="city">Suita</named-content></addr-line>, <country>Japan</country></aff><aff id="aff3"><institution content-type="dept">Gastrointestinal Surgery</institution>, <institution>Osaka University</institution>, <addr-line><named-content content-type="city">Suita</named-content></addr-line>, <country>Japan</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-109554"><name><surname>Postovit</surname><given-names>Lynne-Marie</given-names></name><role>Reviewing editor</role><aff><institution>University of Alberta</institution>, <country>Canada</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>akikuchi@molbiobc.med.osaka-u.ac.jp</email> (AK);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>30</day><month>09</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e66721</elocation-id><history><date date-type="received"><day>20</day><month>01</month><year>2021</year></date><date date-type="accepted"><day>29</day><month>09</month><year>2021</year></date></history><permissions><copyright-statement>Â© 2021, Harada et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Harada et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66721-v1.pdf"/><abstract><p>Pancreatic cancer has a high mortality rate due to metastasis. Whereas KRAS is mutated in most pancreatic cancer patients, controlling KRAS or its downstream effectors has not been succeeded clinically. ARL4C is a small G protein whose expression is induced by the Wnt and EGF-RAS pathways. In the present study, we found that ARL4C is frequently overexpressed in pancreatic cancer patients and showed that its localization to invasive pseudopods is required for cancer cell invasion. IQGAP1 was identified as a novel interacting protein for ARL4C. ARL4C recruited IQGAP1 and its downstream effector, MMP14, to invasive pseudopods. Specific localization of ARL4C, IQGAP1, and MMP14 was the active site of invasion, which induced degradation of the extracellular matrix. Moreover, subcutaneously injected antisense oligonucleotide against ARL4C into tumor-bearing mice suppressed metastasis of pancreatic cancer. These results suggest that ARL4C-IQGAP1-MMP14 signaling is activated at invasive pseudopods of pancreatic cancer cells.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>16H06374</award-id><principal-award-recipient><name><surname>Kikuchi</surname><given-names>Akira</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>18H04861</award-id><principal-award-recipient><name><surname>Kikuchi</surname><given-names>Akira</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001700</institution-id><institution>Ministry of Education, Culture, Sports, Science and Technology</institution></institution-wrap></funding-source><award-id>18H05101</award-id><principal-award-recipient><name><surname>Kikuchi</surname><given-names>Akira</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100008673</institution-id><institution>Yasuda Memorial Medical Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kikuchi</surname><given-names>Akira</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003837</institution-id><institution>Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kikuchi</surname><given-names>Akira</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004206</institution-id><institution>Osaka University</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kikuchi</surname><given-names>Akira</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All protocols used for the animal experiments in this study were approved by the Animal Research Committee of Osaka University, Japan (No. 26-032-048). This information is mentioned in the 'Materials and Methods' section.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>-Sequencing data have been deposited in DDBJ under accession codes DRA011537.-All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for Figures 1-7, Figure 2-figure supplement 1, Figure 2-figure supplement 2, Figure 2-figure supplement 3, Figure 3-figure supplement 1, Figure 3-figure supplement 2, Figure 4-figure supplement 1, Figure 6-figure supplement 1, Figure 7-figure supplement 1, Supplementary File 1 Table 1, and Supplementary File 1 Table 2.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Akikazu Harada</collab></person-group><year iso-8601-date="2021">2021</year><source>Effects of ARL4C ASO on an orthotopic transplantation model.</source><ext-link ext-link-type="uri" xlink:href="https://ddbj.nig.ac.jp/DRASearch/">https://ddbj.nig.ac.jp/DRASearch/</ext-link><comment>DRA011537</comment></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>The Cancer Genome Atlas (TCGA) Research Network</collab></person-group><year iso-8601-date="2020">2020</year><source>Pancreatic Ductal Adenocarcinoma project</source><ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/datapages/">https://xenabrowser.net/datapages/</ext-link><comment>Pancreatic Ductal Adenocarcinoma</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-66721-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>